Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 28;4(9):79.
doi: 10.3390/children4090079.

Assessment of Initial Vancomycin Dosing in Pediatric Oncology Patients

Hillary Orr  1   2 , Deni Trone  3   4 , Joshua Elder  5 , Ashok Raj  6
Affiliations

Assessment of Initial Vancomycin Dosing in Pediatric Oncology Patients

Hillary Orr et al. Children (Basel). .

Abstract

This was a retrospective audit assessing vancomycin dosing of 60 mg/kg/day in the attainment of therapeutic concentrations between 10-20 mcg/mL among 56 pediatric oncology patients. Twelve patients (21%) achieved therapeutic concentrations of 10-20 mcg/mL, while 44 patients (79%) obtained trough levels below 10 mcg/mL despite the addition of nephrotoxic agents.

Keywords: oncology; pediatrics; pharmacokinetics; vancomycin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Libuit J., Whitman A., Wolfe R., Washington C.S. Empiric vancomycin use in febrile neutropenic oncology patients. Open Forum Infect. Dis. 2014;1:1–3. doi: 10.1093/ofid/ofu006. - DOI - PMC - PubMed
    1. Piro C.C., Crossno C.L., Collier A., Ho R., Koyama T., Frangoul H. Initial vancomycin doing in pediatric oncology and stem cell transplant patients. J. Pediatr. Hematol. Oncol. 2009;31:3–7. doi: 10.1097/MPH.0b013e31818b3520. - DOI - PubMed
    1. Chang D., Liem L., Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosing requirements in pediatric cancer patients. Pediatr. Infect. Dis. J. 1994;13:969–974. doi: 10.1097/00006454-199411000-00007. - DOI - PubMed
    1. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., Raad I.I., Rolston K.V., Young J.A., Wingard J.R., et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 updates by Infectious Disease Society of America. Clin. Infect. Dis. 2011;52:e56–e93. doi: 10.1093/cid/cir073. - DOI - PubMed
    1. Sanders S.J.W.J., Bijleveld Y.A., Sinkeler F., Kemper E.M., Pajkrt D., van de Wetering M., van Eijkelenburg N.K., Mathôt R.A. Clinical evaluation of vancomycin dosage in pediatric oncology patients. Pediatr. Infect. Dis. J. 2014;33:731–733. doi: 10.1097/INF.0000000000000268. - DOI - PubMed

LinkOut - more resources